Transplant for MDS: Challenges and emerging strategies

Tamari, Roni; Castro‐Malaspina, Hugo

doi:10.1016/j.beha.2014.11.006

Cited by 4 publications

(2 citation statements)

References 75 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current management in MDS includes supportive care, drug therapy, and allogeneic stem cell transplantation. MDS patients older than age 70 years are not good candidates for allogeneic stem cell transplantation [8,9]. The major complication of MDS patients after allogeneic stem cell transplantation with reduced intensity conditioning is relapse of malignant disease.…”

Section: Ota Fuchsmentioning

confidence: 99%

Introductory Chapter: Myelodysplastic Syndromes

Fuchs¹

2016

Myelodysplastic Syndromes

View full text Add to dashboard Cite

Section: Ota Fuchsmentioning

confidence: 99%

Introductory Chapter: Myelodysplastic Syndromes

Fuchs¹

2016

Myelodysplastic Syndromes

View full text Add to dashboard Cite

“…While several therapies have been developed in recent years, allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative treatment for these patients. However, its use is restricted due to the risk of morbidity and mortality [ 1 ]. In the past decade, as a result of advances in therapy and supportive care, along with wider donor availability, the number of patients with MDS undergoing HCT has been increasing [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant

Tomas

Whiting

Maloy

et al. 2021

Bone Marrow Transplant

Self Cite

View full text Add to dashboard Cite

The post-transplant scoring system (PTSS), developed by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy, is based on three independent post-transplant risk factors: grade of acute graft-versus-host disease, lack of platelet recovery before day 100, and relapse before day 100; discriminating low-(0), intermediate-(1-3), and high-risk (4-8) patients. We investigated the prognostic value of the PTSS in a cohort of patients with MDS who underwent myeloablative CD34-selected TCD transplants. From 2008 to 2018, 109 patients underwent a first TCD-HCT for MDS at our center. We used Cox proportional hazards models and different landmark analyses to evaluate the association of categorized PTSS score risk groups with overall survival (OS). Patients with an intermediate/ high risk PTSS score had decreased OS at day 180 (univariate HR 3.25 [95% CI 1.60, 6.60], p = 0.001) and at day 365 (univariate HR 5.42 [95% CI 2.21, 13.3], p < 0.001) compared to low risk PTSS scores. This association remained significant after adjusting for HCT-CI. PTSS score calculated at day 100 was not associated with OS, even after adjusting for HCT-CI subgroups. In summary, the PTSS predicted survival at day 180 and day 365 in recipients of T-cell-depleted allografts for myelodysplastic syndrome.

show abstract

Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management

2015

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are typical diseases of the elderly, with a median age of 68-75 years at initial diagnosis. Demographic changes producing an increased proportion of elderly in our societies mean the incidence of MDS will rise dramatically. Considering the increasing number of treatment options, ranging from best supportive care to hematopoietic stem cell transplantation (HSCT), decision making is rather complex in this cohort of patients. Moreover, aspects of the aging process also have to be considered in therapy planning. Treatment of elderly MDS patients is dependent on the patient's individual risk and prognosis. Comorbidities play an essential role as predictors of survival and therapy tolerance. Age-adjusted models and the use of geriatric assessment scores are described as a basis for individualized treatment algorithms. Specific treatment recommendations for the different groups of patients are given. Currently available therapeutic agents, including supportive care, erythropoiesis-stimulating agents (ESAs), immune-modulating agents, hypomethylating agents, and HSCT are described in detail and discussed with a special focus on elderly MDS patients. The inclusion of elderly patients in clinical trials is of utmost importance to obtain data on efficacy and safety in this particular group of patients. Endpoints relevant for the elderly should be integrated, including maintenance of quality of life and functional activities as well as evaluation of use of healthcare resources.

show abstract

Transplant for MDS: Challenges and emerging strategies

Cited by 4 publications

References 75 publications

Introductory Chapter: Myelodysplastic Syndromes

Introductory Chapter: Myelodysplastic Syndromes

The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant

Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management

Contact Info

Product

Resources

About